Oxymetazoline compositions and methods for treating ophthalmic diseases
By developing a drug-stabilizing eye fluid containing oxymelatin hydrochloride, it directly acts on the α2 adrenal receptor of the eyelid, the side effects of treating ptosis in the prior art were solved, and a safe and effective upper eyelid lift effect was achieved.
Patent Information
- Application Number
- JP2025014721
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-12-16
- Filing Date
- 2025-01-31
- Publication Date
- 2025-04-17
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The prior art is difficult to effectively treat ptosis without causing side effects, especially drug treatment often leads to optic neuritis, photosensitive and systemic side effects.
A drug-stable ophthalmic drug has been developed, containing 0.1% oxygen melatin hydrochloride, combined with an appropriate amount of buffering and moisturizing agent to form an eye fluid without preservatives, which enhances the upper eyelid by directly acting on the α2 adrenal receptor on the eyelid.
This method can effectively improve the upper eyelid, improve visual field defects, reduce surgical risks, and reduce the risk of eye irritation and allergic reactions due to the preservative-free design.
Smart Images

Figure 2025065198000014 
Figure 2025065198000015 
Figure 2025065198000016
Abstract
Description
[Technical field]
[0001] The present disclosure relates to compositions and methods for treating various ocular disorders, including eyelid drooping or disorders associated with that condition. The present disclosure also relates to compositions comprising oxymetazoline, pharma- ceutically acceptable salts of oxymetazoline, and methods for preparing and using the same. [Background technology]
[0002] Ptosis (commonly known as ptosis) is an abnormal partial or complete drooping of the upper eyelid, usually resulting from partial or complete insufficiency of the muscles that lift the upper eyelid, namely the levator palpebrae superioris and / or the Müller muscle. Ptosis occurs when the muscles that lift the eyelid (levator palpebrae superioris and / or the Müller muscle) are not strong enough to lift properly. It can affect one or both eyes and is more common in older people as the eyelid muscles start to deteriorate. It is one of the most common eyelid disorders, occurring in about 12% of adults over the age of 50 (GV Sridharan, RCTallis, B. Leatherbarrow, W.M. Forman, A., Community Survey of Ptosis of the Eyelid and Pupil Size of Elderly People, Age and Ageing, Volume 24, Issue 1, January 1995, pp. 21-24). Ptosis is classified as either congenital or acquired. Acquired ptosis has numerous etiologies, but is most often aponeurotic, the result of degenerative changes to the levator aponeurosis or stretching or tearing during cataract surgery, lens exchange, or as a result of chronic contact lens wear, both hard and soft. (Custer PL, (2008) Blepharoptosis. In: Yanoff M., Duker JS, editors. Ophthalmology. 3rd ed. St. Louis, MO: Mosby Elsevier; p. 1397-1403; van den Bosch WA, Lemij HG, Blepharoptosis induced by prolonged hard contact lens wear.Ophthalmology.1992;99:1759‐65;Kersten RC,Conciliis C.,Kulwin DR,Acquired ptosis in the young and middle-aged adult population.Ophthalmology.1995;102:924-8;Reddy AK, Foroozan R., Arat YO, Edmond JC, Yen MT, Ptosis in young soft contact lens wearers.Ophthalmology.2007;114:2370).
[0003] Patients with ptosis may experience significant superior visual field defects, which can affect daily activities such as driving, crossing the road, and reading. Treatment of acquired ptosis usually involves surgery, which carries risks of infection, bleeding, over- or undercorrection, decreased vision, and lagophthalmos (inability to completely close the eyelids) (Finsterer J., Ptosis: causes, presentation, and management. Aesthetic Plast. Surg. 2003;27(3):193-204). Mechanical treatment of ptosis (scleral contact lenses with bars that lift the eyelids, ptosis posts attached to glasses, or adhesive tape or putty that attaches the upper eyelid to the supraorbital structures) is limited by patient dissatisfaction with physical appearance, contact allergies, or skin irritation. (Shah-Desai SD, Aslam SA, Pullum K., Beaconsfield M., Rose GE, Scleral contact lens usage in patients with complex blepharoptosis. Ophthal. Plast. Reconstr. Surg. 2011 Mar-Apr;27(2):95-8). Pharmacological treatment of ptosis has not been pursued because the agents evaluated (e.g., epinephrine, dipivefrin, apraclonidine, phenylephrine, brimonidine) either cause pupillary dilation, blurred vision or photophobia, or cause unacceptable systemic side effects. (Matjucha IC, The nonsurgical treatment of ptosis. In:Cohen AJ, Weinberg DA, editors: Evaluation and management of blepharoptosis.New York:Springer,2011.pp.155-61;Scheinfeld N.,The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face.Dermatol.Online J.2005 Mar 1;11(1):9;Kass MA,Mandell AI,Goldberg I.,Paine JM,Becker B.,Dipivefrin and epinephrine treatment of elevated intraocular pressure:a comparative study.Arch.Ophthalmol.1979 Oct;97(10):1865-6;Fraunfelder FT,Scafidi AF,Possible adverse effects from topical ocular 10% phenylephrine.Am.J.Ophthalmol.1978;85(4):447-53).
[0004] Oxymetazoline hydrochloride, 6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol monohydrochloride or Phenol, 3-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethyl-, monohydrochloride, is an alpha-adrenergic agonist. Oxymetazoline is a direct acting sympathomimetic amine that acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. To address the ongoing challenge of balancing efficacy with the relative risk of adverse events, novel ophthalmic formulations of oxymetazoline hydrochloride were developed. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Finsterer J. Aesthetic Plast.Surg.(2003)27(3):193~204 [Non-Patent Document 2] Shah-Desai SD et al. Ophthal.Plast.Reconstr.Surg.(2011)Mar-Apr;27(2):95~8 Summary of the Invention [Means for solving the problem]
[0006] In some embodiments, the disclosed compositions relate to a pharma- ceutically stable aqueous ophthalmic formulation comprising about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally a pH adjuster; wherein the pH of the formulation ranges from about 6.3 to about 6.5. In some embodiments, the one or more suitable buffers comprise about 0.05% to about 1.0% by weight. In some embodiments, the one or more suitable buffers comprise sodium acetate trihydrate and sodium citrate. In some embodiments, the one or more suitable buffers include about 0.39% by weight sodium acetate trihydrate and about 0.17% by weight sodium citrate. In some embodiments, the formulation includes about 0.64% by weight sodium chloride, about 0.075% by weight potassium chloride, about 0.048% by weight calcium chloride dihydrate, and about 0.03% by weight magnesium chloride hexahydrate. In some embodiments, the pH adjuster is selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and combinations thereof. In some embodiments, the pH adjuster includes hydrochloric acid. In some embodiments, the formulation does not include a preservative. In some embodiments, the formulation is stable for 0-24 months. In some embodiments, the formulation is stable for at least 24 months. In some embodiments, the formulation is stable for at least 24 months at 25° C. and 40% relative humidity. In some embodiments, the composition is formulated in a disposable container that contains. In some embodiments, the volume of the disposable container is about 0.5 mL. In some embodiments, the disposable container is in a child-resistant package. In some embodiments, the disposable container delivers about 0.035 mg of oxymetazoline hydrochloride per drop.
[0007] The disclosed compositions also relate to a pharma- ceutically stable aqueous ophthalmic formulation comprising about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally a pH adjuster, wherein the pH of the formulation ranges from about 6.3 to about 6.5. In some embodiments, the one or more suitable buffers comprise about 0.05% to about 1.0% by weight. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate and sodium citrate. In some embodiments, the one or more suitable buffers include about 0.39% by weight sodium acetate trihydrate and about 0.17% by weight sodium citrate. In some embodiments, the formulation includes about 0.64% by weight sodium chloride, about 0.075% by weight potassium chloride, about 0.048% by weight calcium chloride dihydrate, and about 0.03% by weight magnesium chloride hexahydrate. In some embodiments, the pH adjuster is selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and combinations thereof. In some embodiments, the pH adjuster includes hydrochloric acid. In some embodiments, the formulation is stable for 0-24 months. In some embodiments, the formulation is stable for at least 24 months. In some embodiments, the formulation is stable for at least 24 months at 25° C. and 40% relative humidity. In some embodiments, the composition is formulated in a disposable container. In some embodiments, the disposable container has a volume of about 0.5 mL. In some embodiments, the disposable container is in a child resistant package. In some embodiments, the disposable container is in a child resistant pouch. In some embodiments, the disposable container delivers about 0.035 mg of oxymetazoline hydrochloride per drop.
[0008] The compositions of the present disclosure also relate to a pharma- ceutically stable, aqueous, ophthalmic preservative-free formulation comprising: about 0.1% by weight oxymetazoline hydrochloride; about 0.64% by weight sodium chloride; about 0.075% by weight potassium chloride; about 0.048% by weight calcium chloride dihydrate; about 0.03% by weight magnesium chloride hexahydrate; one or more suitable buffers; about 0.5% by weight hypromellose; and optionally hydrochloric acid; wherein the pH of the formulation is in the range of about 6.3 to about 6.5.
[0009] The disclosed method is a method of treating ptosis in a subject, the method comprising administering to at least one eye of the subject a therapeutically effective amount of a pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprising: about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally hydrochloric acid, wherein the pH range of the pharma-ceutical stable, aqueous, ophthalmic formulation is about 6.3 to about 6.5. In some embodiments, the ptosis is acquired aponeurotic ptosis. In some embodiments, the pharma- ceutical stable aqueous ophthalmic formulation is administered to the subject at a dose of one drop in each eye for one or more consecutive days for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride.
[0010] In some embodiments, the mean C after administration of a single dose of the formulation max In some embodiments, the mean AUC 0-∞ In some embodiments, the T after administration of a single dose of the formulation is about 300 to about 700 pg·h / mL. maxIn some embodiments, the disclosed method relates to a method of treating ptosis using a pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprising about 0.64% by weight sodium chloride; about 0.075% by weight potassium chloride; about 0.048% by weight calcium chloride dihydrate; about 0.03% by weight magnesium chloride hexahydrate; and about 0.5% by weight hypromellose.
[0011] The disclosed methods also relate to a method of increasing vertical separation between an upper and lower eyelid of a subject, the method comprising administering to at least one eye of the subject a pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprising: about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally hydrochloric acid, wherein the pharma-ceutical stable, aqueous, ophthalmic formulation has a pH range of about 6.3 to about 6.5.
[0012] In some embodiments, the formulation is administered to the subject in a dose of one drop in a single eye for a total daily dose of about 0.035 mg of oxymetazoline hydrochloride for one or more consecutive days. In some embodiments, the formulation is administered to the subject in a dose of one drop in each eye for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride for one or more consecutive days. In some embodiments, the mean C after administration of a single dose of the formulation is max In some embodiments, the mean AUC 0-∞ In some embodiments, the T after administration of a single dose of the formulation is about 300 to about 700 pg·h / mL. max is about 0.5 to about 6 hours.
[0013] In some embodiments, the pharma- ceutically stable, aqueous, preservative-free ophthalmic formulation comprises about 0.64% by weight sodium chloride; about 0.075% by weight potassium chloride; about 0.048% by weight calcium chloride dihydrate; about 0.03% by weight magnesium chloride hexahydrate; and about 0.5% by weight hypromellose.
[0014] The disclosed method is a method of improving a Leicester Peripheral Field Test (LPFT) score in a subject, the method comprising administering to at least one eye of the subject a pharma- ceutical stabilised, aqueous, preservative-free ophthalmic formulation comprising: about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally hydrochloric acid, wherein The present invention is also directed to a method, wherein the pharma- ceutical stable aqueous ophthalmic formulation has a pH range of about 6.3 to about 6.5, and the mean LPFT score increases by about 5 to 10 points about 0.1 to 16 hours after administration. In some embodiments, the formulation is administered to the subject at a dose of one drop in each eye for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride for one or more consecutive days. In some embodiments, the mean C after administration of a single dose of the formulation is max In some embodiments, the mean AUC 0-∞ In some embodiments, the T after administration of a single dose of the formulation is about 300 to about 700 pg·h / mL. maxIn some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 5 to 10 points about 6 hours after administration. In some embodiments, no tachyphylaxis is demonstrated for at least 6 weeks. In some embodiments, the pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprises about 0.64% by weight sodium chloride; about 0.075% by weight potassium chloride; about 0.048% by weight calcium chloride dihydrate; about 0.03% by weight magnesium chloride hexahydrate; and about 0.5% by weight hypromellose.
[0015] The disclosed method is a method of improving a subject's Marginal Corneal Reflex Distance Test 1 (MRD-1) score, the method comprising administering to at least one eye of the subject a pharma- ceutical stabilised, aqueous, preservative-free ophthalmic formulation comprising: about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally hydrochloric acid, wherein The method also relates to a method in which the pharmacologic stable aqueous ophthalmic formulation has a pH range of about 6.3 to about 6.5, and the mean score increases by about 0.2 to 1.5 points about 1 to 20 minutes after administration or about 1 to 6 hours, e.g., 8 hours after administration. In some embodiments, the pharmacologic stable aqueous ophthalmic formulation is administered to the subject at a dose of one drop in each eye for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride for one or more consecutive days. In some embodiments, the mean C score after administration of a single dose of the formulation is max In some embodiments, the mean AUC 0-∞ In some embodiments, the T after administration of a single dose of the formulation is about 300 to about 700 pg·h / mL. maxIn some embodiments, the mean score of the Marginal Corneal Reflex Distance Test 1 (MRD-1) increases by about 0.2 to 1.0 points about 5 minutes after administration. In some embodiments, tachyphylaxis is not exhibited for at least 6 weeks. In some embodiments, the pharma- ceutically stable aqueous ophthalmic preservative-free formulation comprises about 0.64% sodium chloride by weight; about 0.075% potassium chloride by weight; about 0.048% calcium chloride dihydrate by weight; about 0.03% magnesium chloride hexahydrate by weight; and about 0.5% hypromellose by weight. In some embodiments, the use of the compositions and methods of the present invention does not exhibit tachyphylaxis. In some embodiments, tachyphylaxis is not exhibited for 6 weeks. In some embodiments, tachyphylaxis is not exhibited for a period of 6 weeks to 3 months. In some embodiments, tachyphylaxis is not exhibited for a period of 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 1 month, 2 months, or 3 months. In some embodiments, tachyphylaxis is not exhibited during use of the compositions or methods of the present disclosure. The present disclosure relates to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long-term storage.The present disclosure also relates to compositions comprising oxymetazoline and methods of treating various ocular disorders associated with drooping eyelids, such as ptosis, in a subject comprising administering to the subject a composition comprising oxymetazoline. [Brief description of the drawings]
[0016] [Figure 1] FIG. 1 shows the average concentrations achieved after single-dose topical administration of 0.1% by weight oxymetazoline hydrochloride ophthalmic solution using one drop in each eye.
[0017] [Diagram 2] FIG. 2 shows a diagram of the Leicester Peripheral Field Test.
[0018] [Figure 3A]FIG. 3A and FIG. 3B show 24-month and 30-month stability data for oxymetazoline composition batch R60681. [Figure 3B] FIG. 3A and FIG. 3B show 24-month and 30-month stability data for oxymetazoline composition batch R60681.
[0019] [Figure 4A] FIG. 4A and FIG. 4B show 24-month and 30-month stability data for oxymetazoline composition batch R60701. [Figure 4B] FIG. 4A and FIG. 4B show 24-month and 30-month stability data for oxymetazoline composition batch R60701.
[0020] [Figure 5A] FIG. 5A and FIG. 5B show 24-month and 30-month stability data for oxymetazoline composition batch R60711. [Figure 5B] FIG. 5A and FIG. 5B show 24-month and 30-month stability data for oxymetazoline composition batch R60711. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] I. Definition Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs.In case of conflict, the present application, including definitions, will control.Unless otherwise required by context, singular terms shall include plurals and plural terms shall include singulars.All publications, patents and other references mentioned herein are incorporated by reference in their entirety for all purposes as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
[0022] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and are not intended to be limiting. Other features and advantages of the present disclosure will be apparent from the detailed description and claims.
[0023] In order to further define this disclosure, the following terms and definitions are provided.
[0024] The singular forms "a," "an," and "the" include plural referents unless the context clearly indicates otherwise. The term "a" (or "an"), as well as the terms "one or more," and "at least one," may be used interchangeably herein. In certain embodiments, the term "a" or "an" means "single." In other embodiments, the term "a" or "an" includes "two or more" or "plural."
[0025] The term "about" is used herein to mean about, roughly, around, or within the region thereof. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" is used herein to modify numerical values above and below the set forth value by a variance of 10 percent (higher or lower).
[0026] The term "and / or" as used herein should be construed as specifically disclosing each of the two specified features or components with or without the other. Thus, the term "and / or" as used herein in phrases such as "A and / or B" is intended to include "A and B", "A or B", "A" (single), and "B" (single). Similarly, the term "and / or" as used in phrases such as "A, B, and / or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (single); B (single); and C (single).
[0027] As used herein, "pharmacologically acceptable" refers to compounds, materials, compositions, and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without undue toxicity, irritation, allergic response, or other problem or complication, and commensurate with a reasonable benefit / risk ratio.
[0028] The term "pharmaceutical stable" refers to the ability of a pharmaceutical dosage form to maintain its physical, chemical, therapeutic and microbial properties during storage and use by a patient.
[0029] As used herein, the term "effective amount" or "pharmacologically effective amount" refers to an amount or quantity of a drug or pharma- ceutical active agent sufficient to elicit the necessary or desired therapeutic response, in other words, an amount sufficient to elicit an appreciable biological response when administered to a patient.
[0030] As used herein, the term "unit dosage form" or "unit dose composition" refers to a device containing a quantity of a therapeutic compound, said quantity being such that one or more predetermined units can be provided as a single therapeutic administration.
[0031] As used herein, the term "wt. %" or "wt. / volume" refers to the ratio between components relative to volume. For example, a 5 wt. % ethanol solution in water would represent a solution containing 5 g of ethanol for every 100 mL of water.
[0032] As used herein, "C max " refers to the maximum plasma concentration of a drug after it is administered to a subject.
[0033] As used herein, "T max The term "maximum plasma concentration ("C") after administration of a drug max " refers to the time required to reach a certain level of
[0034] As used herein, the term "AUC" refers to the area under the curve of a plot of plasma concentration versus time after administration of the drug.
[0035] As used herein, "AUC 0-t The term "time from time zero to the last measurable concentration (C t ) refers to the area under the drug concentration-time curve.
[0036] As used herein, "AUC 0-∞ The term "area under the drug concentration-time curve from time zero to infinity." AUC 0-∞ is the extent of drug absorption relative to the last measured concentration (AUC 0-T ) and extrapolated to infinity (AUC t-∞ ).
[0037] The term "free base equivalent" or "FBE" as used herein refers to the amount of oxymetazoline present in oxymetazoline or its salts. In other words, the term "FBE" refers to either the amount of oxymetazoline free base or the equivalent amount of oxymetazoline free base provided by a salt of oxymetazoline. For example, due to the weight of the hydrochloride salt, 100 mg of oxymetazoline hydrochloride provides as much oxymetazoline as 88 mg of the free base form of oxymetazoline. Other salts are expected to have different conversion factors depending on the molecular weight of the salt.
[0038] The term "Leicester Peripheral Field Test" or "LPFT" refers to a customized visual field test specifically designed to assess ptosis (Ho SF, Morawski A., Sampath R., Burns J., Modified visual field test for ptosis surgery (Leicester Peripheral Field Test). Eye (Lond). 2011 Mar; 25 (3): 365-9. doi: 10.1038 / eye.2010.210. Epub 2011 Jan 21) and is performed using a Humphrey Visual Field Analyzer. It is an age-corrected screening test in which 35 points are tested in the superior visual field and 14 points are tested in the inferior visual field. A maximum of 48° is tested in the superior visual field. The center of fixation is shifted 15° inferiorly to allow for maximum superior visual field testing. The inferior visual field test serves as a baseline but is not used in the analysis.
[0039] The term "Marginal Reflex Distance 1 (MRD)" refers to one of two tests. MRD-1 refers to a test that uses a photographic measurement of the distance from the central pupillary light reflex to the central margin of the upper eyelid. An external digital photograph is used to measure MRD-1. The measurement is based on the distance from the central pupillary light reflex to the central margin of the upper eyelid, ≦2 mm (a visible central pupillary light reflex does not default to 0). MRD-2 refers to a measurement of the perpendicular distance from the center of the pupil and the margin of the lower eyelid.
[0040] The term "treat" or "treatment" as used herein refers to the administration of a composition to a subject for therapeutic purposes.
[0041] The term "mean" refers to the average value of a patient population. For example, "mean Cmax" refers to the average maximum plasma concentration value of a drug in a patient population.
[0042] The term "adult" refers to a person 18 years of age or older.
[0043] II. Composition The compositions of the present disclosure include an effective amount of an α-adrenergic agonist formulated for ocular administration. The present disclosure provides compositions and methods useful in the treatment of ptosis. In some embodiments, the compositions are eye drops. In some embodiments, oxymetazoline hydrochloride is formulated for local ocular delivery as a sterile, preservative-free eye drop (eye drop) prepared aseptically. The eye drop may comprise 0.1% by weight oxymetazoline hydrochloride in a balanced salt solution with added viscosity modifier (hypromellose). The eye drop may be filled into clear, unit-dose 0.5 mL low-density polyethylene (LDPE) blow-fill-seal (BFS) vials, which may be individually packaged in foil pouches.
[0044] When administered at 0.1% by weight, oxymetazoline is believed to stimulate alpha-2 adrenergic receptors in the Muller muscle, causing it to contract, thereby lifting the upper eyelid and slightly contracting the lower eyelid.
[0045] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation consisting of about 0.1% by weight oxymetazoline hydrochloride; about 0.2% to about 1.0% by weight sodium chloride; about 0.05% to about 0.10% by weight potassium chloride; about 0.02% to about 0.06% by weight calcium chloride; about 0.01% to about 0.05% by weight magnesium chloride; one or more suitable buffers; about 0.1% to about 0.90% by weight hypromellose; and optionally a pH adjuster; and the pH range of the formulation is about 6.3 to about 6.5.
[0046] In some embodiments, the one or more suitable buffers comprise about 0.05% to about 1.0% by weight. In some embodiments, the one or more suitable buffers comprise sodium acetate trihydrate and sodium citrate. In some embodiments, the formulation comprises about 0.64% by weight sodium chloride, about 0.075% by weight potassium chloride, about 0.048% by weight calcium chloride dihydrate, and about 0.03% by weight magnesium chloride hexahydrate. In some embodiments, the pH adjuster is selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and combinations thereof. In some embodiments, the pH adjuster comprises hydrochloric acid.
[0047] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation comprising 0.1 wt. % oxymetazoline hydrochloride; 0.64 wt. % sodium chloride; 0.075 wt. % potassium chloride; 0.048 wt. % calcium chloride dihydrate; 0.03 wt. % magnesium chloride hexahydrate; one or more suitable buffers; 0.5 wt. % hypromellose; and optionally hydrochloric acid; the formulation has a pH range of 6.3-6.5. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, tris(hydroxymethyl)aminomethane (TRIS), and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In one embodiment, the one or more suitable buffers comprise 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0048] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation consisting essentially of 0.1 wt. % oxymetazoline hydrochloride; 0.64 wt. % sodium chloride; 0.075 wt. % potassium chloride; 0.048 wt. % calcium chloride dihydrate; 0.03 wt. % magnesium chloride hexahydrate; one or more suitable buffers; 0.5 wt. % hypromellose; and optionally hydrochloric acid; the pH range of the formulation is 6.3-6.5. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In one embodiment, the one or more suitable buffers comprise 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0049] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation consisting of 0.1 wt. % oxymetazoline hydrochloride; 0.64 wt. % sodium chloride; 0.075 wt. % potassium chloride; 0.048 wt. % calcium chloride dihydrate; 0.03 wt. % magnesium chloride hexahydrate; one or more suitable buffers; 0.5 wt. % hypromellose; and optionally hydrochloric acid; the pH range of the formulation is 6.3-6.5. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In one embodiment, the one or more suitable buffers include 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0050] One aspect of the present disclosure is a method for treating ptosis in a subject. The method includes administering an effective amount of oxymetazoline to an eye of a subject in need of such treatment. In some embodiments, the method includes administering to at least one eye of the subject a therapeutically effective amount of a pharma- ceutical stable aqueous ophthalmic formulation comprising 0.1% by weight oxymetazoline hydrochloride; 0.64% by weight sodium chloride; 0.075% by weight potassium chloride; 0.048% by weight calcium chloride dihydrate; 0.03% by weight magnesium chloride hexahydrate; one or more suitable buffers; 0.5% by weight hypromellose; and optionally hydrochloric acid; the pH range of the formulation is 6.3-6.5. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In one embodiment, the one or more suitable buffers include 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0051] In some aspects of the disclosure, the subject is a mammal. In other aspects, the mammal is a human.
[0052] In some embodiments, the formulation is administered at a total daily dose of about 0.07 mg of oxymetazoline hydrochloride. In some embodiments, the average weight of one drop is 0.035 g. In some embodiments, one drop is administered to each eye, each drop containing approximately 0.035 mg of oxymetazoline hydrochloride (0.0308 mg of oxymetazoline free base).
[0053] In some embodiments, the method includes administering to at least one eye of a subject a therapeutically effective amount of a pharma- ceutically stable aqueous ophthalmic formulation consisting essentially of 0.1% by weight oxymetazoline hydrochloride; 0.64% by weight sodium chloride; 0.075% by weight potassium chloride; 0.048% by weight calcium chloride dihydrate; 0.03% by weight magnesium chloride hexahydrate; one or more suitable buffers; 0.5% by weight hypromellose; and optionally hydrochloric acid; the formulation has a pH range of 6.3-6.5. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In some embodiments, the one or more suitable buffers comprise 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate. In some embodiments, the formulation is administered in an amount of about 0.07 mg.
[0054] In some embodiments, the method includes administering to at least one eye of a subject a therapeutically effective amount of a pharma- ceutically stable aqueous ophthalmic formulation consisting of 0.1% oxymetazoline hydrochloride by weight; 0.64% sodium chloride by weight; 0.075% potassium chloride by weight; 0.048% calcium chloride dihydrate by weight; 0.03% magnesium chloride hexahydrate by weight; one or more suitable buffers; 0.5% hypromellose by weight; and optionally hydrochloric acid; the formulation has a pH range of 6.3-6.5. In some embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In some embodiments, the one or more suitable buffers comprise 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0055] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation comprising 0.1% by weight oxymetazoline hydrochloride; 0.64% by weight sodium chloride; 0.075% by weight potassium chloride; 0.048% by weight calcium chloride dihydrate; 0.03% by weight magnesium chloride hexahydrate; one or more suitable buffers; 0.5% by weight hypromellose; and optionally hydrochloric acid; the pH range of the formulation is 6.3-6.5. In other embodiments, the one or more suitable buffers include boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In some embodiments, the one or more suitable buffers include 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0056] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation comprising about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1.0% by weight of metazoline hydrochloride. In some embodiments, the solution is a pharma-ceutically stable aqueous ophthalmic formulation comprising about 0.10%, about 0.12%, about 0.13%, about 0.14%, about 0.15%, about 0.16%, about 0.17%, about 0.18%, about 0.19%, or about 0.20% by weight of metazoline hydrochloride. In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation comprising about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, or about 0.09% metazoline hydrochloride by weight.
[0057] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation consisting essentially of 0.1% by weight oxymetazoline hydrochloride; 0.64% by weight sodium chloride; 0.075% by weight potassium chloride; 0.048% by weight calcium chloride dihydrate; 0.03% by weight magnesium chloride hexahydrate; one or more suitable buffers; 0.5% by weight hypromellose; and optionally hydrochloric acid; the pH range of the formulation is 6.3-6.5. In other embodiments, the one or more suitable buffers include boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In some embodiments, the one or more suitable buffers include 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0058] In some embodiments, the solution is a pharma- ceutically stable aqueous ophthalmic formulation consisting of 0.1 wt. % oxymetazoline hydrochloride; 0.64 wt. % sodium chloride; 0.075 wt. % potassium chloride; 0.048 wt. % calcium chloride dihydrate; 0.03 wt. % magnesium chloride hexahydrate; one or more suitable buffers; 0.5 wt. % hypromellose; and optionally hydrochloric acid; the pH range of the formulation is 6.3-6.5. In other embodiments, the one or more suitable buffers include sodium acetate trihydrate, sodium citrate, boric acid, sodium borate, potassium citrate, citric acid, sodium bicarbonate, TRIS, and various mixed phosphate buffers (including combinations of Na2HPO4, NaH2PO4, and KH2PO4) and mixtures thereof. In some embodiments, the one or more suitable buffers comprise 0.39% by weight sodium acetate trihydrate and 0.17% by weight sodium citrate.
[0059] In one embodiment, the formulation comprises sodium chloride and the amount of sodium chloride in the formulation is about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, or about 1.0% by weight.
[0060] In one embodiment, the formulation comprises potassium chloride and the amount of potassium chloride in the formulation is about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, or about 0.5% by weight.
[0061] In one embodiment, the formulation comprises calcium chloride, and the amount of calcium chloride in the formulation is about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, or about 0.2% by weight.
[0062] In one embodiment, the formulation comprises magnesium chloride and the amount of magnesium chloride in the formulation is about 0.01%, about 0.02%, about 0.03%, about 0.04%, about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09%, about 0.1%, or about 0.2% by weight.
[0063] In one embodiment, the formulation comprises hypromellose, and the amount of hypromellose in the formulation is about 0.08%, about 0.09%, about 0.1%, about 0.2%, about 0.3%, about 0.4%, about 0.5%, about 0.6%, about 0.7%, about 0.8%, about 0.9%, about 1.0%, or about 2.0% by weight.
[0064] In some embodiments, oxymetazoline is provided as a pharma- ceutically acceptable salt of oxymetazoline. The term "pharma- ceutically acceptable salt" is art-recognized and refers to relatively non-toxic inorganic and organic acid addition salts of the disclosed compositions or any of their components, including, but not limited to, therapeutic agents, excipients, other materials, and the like. Examples of pharma- ceutically acceptable salts include those derived from mineral acids, such as hydrochloric acid and sulfuric acid, and those derived from organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the like. Examples of inorganic bases suitable for forming salts include, but are not limited to, hydroxides, carbonates, bicarbonates of mania, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc, and the like. Salts can also be formed with suitable organic bases, including those that are non-toxic and strong enough to form such salts.
[0065] III. Composition stability The composition of the present disclosure is stable.Long-term stability is an important attribute to consider when preparing ophthalmic formulations, especially preservative-free formulations.In order to ensure the long-term stability of a composition, various important quality attributes must be maintained throughout the shelf life of the composition, including assay, osmolality, impurities, viscosity, weight loss, and sterility.These attributes are affected by various factors, including temperature, relative humidity, and / or pH.
[0066] Osmolality is the concentration of all solutes in a given weight of water, expressed as one or the other unit of osmolality, and is an important attribute in the maintenance of ophthalmic formulations. Since the osmolality of the eye of most subjects is approximately 300 mOsm, it is important that any formulation administered to the eye be maintained near this range, e.g., about 290 to about 365 mOsm / kg, to ensure that the formulation is well tolerated.
[0067] The stability of the pH of the solution is also important for comfort and safety. If components of an ophthalmic formulation change the pH over time, the formulation may become unstable. Also, changes in pH can cause administration of the formulation that can damage the eye. Therefore, it is important that the desired physiological pH is maintained throughout the life of the formulation. Maintaining the pH near neutral and preserving the natural pH of the eye is important for safety.
[0068] Viscosity is an important quality of ophthalmic formulations to maintain the residence time of the formulation in the eye. It is important that the viscosity of the formulation is maintained throughout the life of the formulation so that the viscosity remains constant and the delivery and residence time of the active ingredient is maintained. For example, in one embodiment, the viscosity is about 15 to about 35 cPs to maintain residence time in the eye and eye comfort.
[0069] Unstable solutions can decompose over time and produce undesirable degradation products. These products can be the result of undesirable chemical reactions involving the active ingredient, including hydrolysis and oxidation. Solution instability with respect to degradation products can cause both toxicity as a result of the production of these impurities and a decrease in the concentration of the active ingredient due to degradation. Undesirable degradation products include N-(2-aminoethyl)-2-[4-(1,1-dimethylethyl)-3-hydroxy-2,6-dimethylphenyl]acetamide, hydroxylated imidazoline derivatives, hydroxylamines, and N-oxide derivatives. Non-limiting examples of degradation products produced from oxymetazoline decomposition include the following: [ka]
[0070] Therefore, the presence of these degradation products must be limited and monitored as the formulation ages to prevent potential loss of activity of the active ingredient and potential undesirable toxicity from the degradation products that arise.
[0071] Maintaining the sterility of the formulation is also important. Sterility testing ensures that ophthalmic formulations are free of contamination with microorganisms that may cause infection or other complications.
[0072] Maintaining the moisture content in a formulation is important to maintain the desired concentration of the components present in the formulation. Thus, the loss of water weight will affect the concentration of the components. Maintaining and monitoring the degradation of components is also important, as degradation products can also affect the concentration of the components, the pH of the solution, and can introduce undesirable contaminants that can pose a risk to eye safety. Limiting degradation products is important for the safety of the drug product, and formulation and process variables can affect degradation products.
[0073] In some embodiments, the compositions of the present disclosure are stable for about 3 months, about 6 months, about 9 months, about 12 months, about 14 months, about 18 months, about 21 months, about 24 months, about 30 months, about 36 months, about 42 months, about 48 months, about 54 months, or about 60 months. In some embodiments, the compositions of the present disclosure are stable for about 3 months. In some embodiments, the compositions of the present disclosure are stable for about 6 months. In some embodiments, the compositions of the present disclosure are stable for at least about 9 months. In some embodiments, the compositions of the present disclosure are stable for at least about 12 months. In some embodiments, the compositions of the present disclosure are stable for at least about 14 months. In some embodiments, the compositions of the present disclosure are stable for at least about 18 months. In some embodiments, the compositions of the present disclosure are stable for about 21 months. In some embodiments, the compositions of the present disclosure are stable for at least about 24 months. In some embodiments, the compositions of the present disclosure are stable for at least about 30 months. In some embodiments, the compositions of the present disclosure are stable for at least about 36 months. In some embodiments, the compositions of the present disclosure are stable for at least about 42 months. In some embodiments, the compositions of the present disclosure are stable for at least about 48 months. In some embodiments, the compositions of the present disclosure are stable for at least about 54 months. In some embodiments, the compositions of the present disclosure are stable for at least about 60 months.
[0074] Stability is also affected by the environmental conditions present during storage. For example, ambient temperature and / or humidity can affect the long-term stability of ophthalmic preparations. In some embodiments, the compositions of the present disclosure are stable at temperatures of about 4°C to about 30°C, about 4°C to about 25°C, about 4°C to about 20°C, about 10°C to about 20°C, about 15°C to about 20°C, or about 20°C to about 30°C. In some embodiments, the compositions of the present disclosure are stable at temperatures of about 15°C, about 16°C, about 17°C, about 18°C, about 19°C, about 20°C, about 21°C, about 22°C, about 23°C, about 24°C, about 25°C, about 26°C, about 27°C, about 28°C, about 29°C, or about 30°C.
[0075] In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 10% to about 70%, about 20% to about 60%, about 30% to about 50%, about 20% to about 80%, about 30% to about 70%, or about 40% to about 60%. In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 10% to about 70%. In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 40% to about 60%. In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or about 80%. In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 10%. In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 20%. In some embodiments, the composition of the present disclosure is stable at a relative humidity of about 30%. In some embodiments, the composition of the present disclosure is stable at about 40% relative humidity. In some embodiments, the composition of the present disclosure is stable at about 50% relative humidity. In some embodiments, the composition of the present disclosure is stable at about 60% relative humidity. In some embodiments, the composition of the present disclosure is stable at about 70% relative humidity. In some embodiments, the composition of the present disclosure is stable at about 80% relative humidity.
[0076] IV. Treatment Method The upper eyelid is usually lifted by contraction of the levator palpebrae superioris (levator muscle) and Müller muscle. Ptosis creates a tired appearance that may be cosmetically undesirable; in more severe cases, ptosis may impede vision in the affected eye or eyes. In addition to fatigue and age-related weakening of the levator and Müller muscles as the underlying cause of ptosis, there are numerous other conditions that are recognized to cause ptosis. For example, ptosis may be due to myogenic, neurogenic, aponeurotic, mechanical, or traumatic causes; ptosis usually occurs in isolation, but may also be associated with various other conditions, such as genetic, immune, or degenerative diseases, tumors, and infections. The method of the present disclosure is useful for treating ptosis. In some embodiments, a therapeutically effective amount of oxymetazoline hydrochloride is delivered in an ophthalmologically acceptable carrier. In some embodiments, the carrier is an emulsion, suspension, gel, ointment, or solution.
[0077] In certain embodiments, the solution is a topical eye drop administered as eye drops. Myogenic causes of ptosis may include diseases that can cause muscle weakness or nerve damage, such as myasthenia gravis and chronic progressive external ophthalmoplegia. Dystrophies or hypoplasia of the superior levator and / or Müller muscles are the most common causes of congenital ptosis. Ptosis may be caused by damage to the third cranial nerve (oculomotor nerve), which controls the muscle that elevates the upper eyelid. Congenital neurogenic ptosis is thought to be caused by Horner syndrome (also known as Horner's syndrome), in which mild ptosis due to paresis of Müller muscle may be associated with ipsilateral miosis (pupil constriction) and anhidrosis. Acquired Homer syndrome may occur after trauma, neoplastic invasion, or even after vascular disease. Acquired ptosis is generally caused by aponeurotic ptosis. This can occur as a result of aging, dehiscence or transection of the levator aponeurosis.
[0078] Additionally, the same effect can be achieved with chronic inflammation or intraocular surgery. Ptosis due to trauma can occur following eyelid laceration due to amputation of the elevator muscle or disruption of neural input. Other causes of ptosis include eyelid neoplasms, neurofibromas, or scar formation following inflammation or surgery. Mild ptosis can occur with aging. Surprisingly, through the process of evaluating many agents across a range of concentrations of such agents, it has been found that certain alpha adrenergic agonists, including oxymetazoline hydrochloride 0.1% by weight, in particular, provide highly effective compositions that provide surprising treatment outcomes as measured by performance on the Leicester Peripheral Field Test (LPFT). This composition can be used to treat ptosis, which has been found to last for 4 to 10 hours, or in one embodiment, 6 hours, following topical administration of one drop of such agent to the affected eye.
[0079] It has also been surprisingly found, through the process of evaluating many agents over a range of concentrations of such agents, that certain alpha adrenergic agonists, including oxymetazoline hydrochloride 0.1% by weight, provide highly effective compositions that provide surprising treatment outcomes as measured by marginal corneal reflex distance test (MRD-1) performance. It has also been found that the compositions can be used to treat ptosis, which lasts for 4-10 hours, or even 6 hours, following topical administration of a single drop of such agent to the affected eye. A rapid onset of effect of oxymetazoline hydrochloride 0.1% by weight was also found, demonstrating improvement in ptosis 5 minutes after administration of the disclosed composition. It has also been found that the improvement in MRD-1 performance lasted for at least 6 hours after administration of the dose. It has also been found that the improvement in MRD-1 performance lasted for at least 8 hours. The compounds and methods of the present disclosure did not exhibit tachyphylaxis, which rapidly diminishes the response to successive doses of the drug, reducing the effectiveness of the drug. In some embodiments, tachyphylaxis is not exhibited for 6 weeks. In some embodiments, tachyphylaxis is not exhibited for a period of 6 weeks to 3 months. In some embodiments, tachyphylaxis is not exhibited for a period of 6 weeks, 7 weeks, 9 weeks, 10 weeks, 11 weeks, 1 month, 2 months, or 3 months. In some embodiments, tachyphylaxis is not exhibited during use of the compositions or methods of the present disclosure. In some embodiments, tachyphylaxis is not exhibited for a period of about 1 week, about 90 days, about 180 days, or about 1 year. In some embodiments, tachyphylaxis is not exhibited for a period of about 1 year, about 2 years, about 3 years, about 5 years, or about 10 years.
[0080] One aspect of the present disclosure is a method for treating ptosis in a subject. The method includes topically administering an effective amount of oxymetazoline to the outer surface of the eye of a subject in need of such treatment. As used herein, "treat" refers to reducing the severity of a condition or disease in a subject having such a condition or disease, even if only temporarily. In one aspect, reducing is removing, even if only temporarily. For example, the ptosis of a subject is said to be treated according to this method when the ptosis is reduced or removed, even if only temporarily.
[0081] The disclosed method is also related to treating other eyelid diseases or non-specific conditions, where the condition is treated by lifting the eyelid.Other conditions that can be treated by the disclosed formulation include Horner's syndrome and myasthenia gravis.The disclosed method can be used to treat other clinical conditions related to the eye, such as eye disorders or eye diseases.The disclosed method comprises administering a therapeutically effective amount of the disclosed composition to at least one eye of a subject in need of such treatment. In some embodiments, clinical conditions related to the eye include dry eye syndrome (e.g., keratoconjunctivitis sicca), Sjogren's syndrome, congenital anlacrimation, xerophthalmia (dry eye due to vitamin A deficiency), keratomalacia, thyroid eye disease, ocular rosacea, eyelid disorders, meibomian gland disease, meibomian gland dysfunction, ectropion, blepharitis, cutis blepharophakia, sarcoidosis, stye, hordeolum, chalazion, ptosis, pterygium, eyelid edema, eyelid dermatitis, trichiasis, eyelash loss, dacryoadenitis, Stevens-Johnson syndrome, ocular graft versus host disease, dacryocystitis, conjunctivitis, keratoconjunctivitis, blepharoconjunctivitis, allergic conjunctivitis, vernal conjunctivitis, conjunctival congestion, conjunctival hyperemia ... suffusion, conjunctivochalasis, subconjunctival hemorrhage, pterygium, pinguecula, conjunctival edema, iritis, iridocyclitis, glaucoma, ocular hypertension, red eye, keratitis, scleritis, episcleritis, peripheral ulcerative keratitis, neurotrophic keratitis, neurotrophic eye disease, corneal ulcer, ulcerative keratitis, corneal abrasion, photokeratitis, ultraviolet keratitis, lagophthalmos keratitis, and corneal dystrophies.
[0082] Other conditions include postoperative inflammation following ophthalmic surgery (e.g., eyelid surgery, cataract surgery, corneal surgery, refractive surgery including photorefractive keratectomy, glaucoma surgery, lacrimal gland surgery, conjunctival surgery, eye muscle surgery, physical trauma, eye conditions caused by the following autoimmune or vascular disorders: rheumatoid arthritis, juvenile rheumatoid arthritis, ankulosing spondylitis, Reiter's syndrome, enteropathic arthritis, psoriatic arthritis, discoid and systemic lupus erythematosus, multiple sclerosis, Graves' disease, antiphospholipid antibody syndrome, sarcoidosis, Wegener's granulomatosis, Behcet's syndrome, polyarteritis nodosa, Takayasu's arteritis, dermatomyositis, psoriasis, relapsing polychondritis, vasculitis, sickle cell anemia, type II diabetes mellitus, diabetic retinopathy, and combinations thereof.
[0083] V. Dosing Frequency and Dose Escalation According to the present disclosure, a subject (e.g., a human) with or at risk of having ptosis is administered any of the pharmaceutical compositions described herein. In some embodiments, the pharmaceutical composition is administered at a constant therapeutically effective amount from the beginning of treatment. The therapeutically effective amount may comprise 0.1% by weight oxymetazoline hydrochloride, one drop for each eye. In one embodiment, the dose comprises 2 drops of about 0.035 g / drop of a 0.1% by weight solution for a total dose of about 0.07 mg, and each drop of the pharmaceutical composition comprises about 0.035 mg of oxymetazoline hydrochloride.
[0084] The pharmaceutical compositions can be administered in unit doses three times a day, twice a day, or once a day, with a total daily dose of the composition being about 0.005 g, about 0.01 g, about 0.02 g, about 0.03 g, about 0.04 g, about 0.05 g, about 0.06 g, about 0.07 g, about 0.08 g, about 0.09 g, or about 0.10 g. The pharmaceutical composition containing 0.1% by weight of oxymetazoline hydrochloride can be administered in a unit dose three times a day, twice a day, or once a day, and the total daily dose of oxymetazoline hydrochloride is about 0.050mg, about 0.010mg, about 0.020mg, about 0.030mg, about 0.035mg, about 0.040mg, about 0.050mg, about 0.060mg, about 0.070mg, about 0.080mg, about 0.090mg, about 0.1mg, about 0.14mg, or about 0.21mg. In some embodiments, the pharmaceutical composition is administered in a unit dose three times a day, twice a day, or once a day to each eye. In some embodiments, the total daily dose of the composition is about 0.07mg, about 0.14mg, or about 0.21mg.
[0085] In some embodiments, the formulation is administered in an amount of about 0.07mg. In some embodiments, the formulation is administered in a dose of 1 drop to a single eye for 1 or more consecutive days for a total daily dose of about 0.035mg. In some embodiments, the formulation is administered in a dose of 1 drop to each eye for 1 or more consecutive days for a total daily dose of about 0.07mg of oxymetazoline hydrochloride.
[0086] In one embodiment, the pharmaceutical composition is administered once a day to one or both eyes. In one embodiment, the pharmaceutical composition is administered in the morning. In one embodiment, the pharmaceutical composition is administered in the afternoon. In one embodiment, the pharmaceutical composition is administered in the evening. In one embodiment, the pharmaceutical composition is administered more than 4 hours before going to bed. In some embodiments, the pharmaceutical composition containing oxymetazoline or a pharma- ceutically acceptable salt thereof is administered twice a day or once a day in a unit dose containing about 0.015 mg, about 0.035 mg, or about 0.07 mg. In some embodiments, one drop is administered to each eye during each dose administration. In some embodiments, one drop is administered to only one eye during each dose administration.
[0087] VI. Pharmaceutical Compositions Another aspect of the present disclosure relates to a pharmaceutical composition comprising oxymetazoline hydrochloride. For ophthalmic applications, preferably the solution is prepared using physiological saline solution as a vehicle. The pH of such eye drops is preferably maintained between 4.5 and 8.0 by a suitable buffer system. Ideally, the pH of such solutions is maintained between 6.3 and 6.5. The formulation may also include conventional pharma- ceutically acceptable stabilizers and surfactants. Tonicity adjusters may be added as necessary or convenient. These include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjuster. Various buffers and means for adjusting pH may be used, so long as the resulting preparation is ophthalmically acceptable. Thus, buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. In some embodiments, the pharmaceutical composition is an ophthalmic dosage form. The present disclosure is not limited to a particular ophthalmic dosage form, and any dosage form capable of delivering oxymetazoline hydrochloride to a patient is suitable for the present disclosure, so long as the dosage form achieves the pharmacokinetic and therapeutic effects described in this disclosure.
[0088] In one embodiment, the formulation does not contain one or more preservatives.
[0089] In some embodiments, the pharmaceutical composition comprises an adsorbent, an antioxidant, a buffer, and / or a diluent.
[0090] As used herein, the term "adsorbent" is intended to mean an agent capable of holding other molecules on its surface by physical or chemical (chemisorption) means. Examples of such compounds include, but are not limited to, powdered charcoal and activated charcoal, and other materials known to those skilled in the art.
[0091] As used herein, the term "antioxidant" refers to an agent that inhibits oxidation and is therefore intended to be used to prevent the deterioration of preparations by the oxidative process.Such compounds include, by way of example and without limitation, ascorbic acid, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium ascorbate, sodium bisulfite, sodium citrate, sodium formaldehyde sulfoxylate and sodium metabisulfite and other materials known to those skilled in the art.
[0092] As used herein, the term "buffering agent" is intended to mean a compound used to resist changes in pH due to dilution or addition of acid or alkali. Such compounds include, by way of example and without limitation, potassium metaphosphate, potassium phosphate, monobasic sodium acetate and sodium citrate anhydrous and dihydrate, as well as other materials known to those skilled in the art.
[0093] VII. Leicester Peripheral Field Test (LPFT) The efficacy of the compositions of the present disclosure can be evaluated using a variety of tests to assess patient improvement. In some embodiments, the Leicester Peripheral Field Test (LPFT) is used to evaluate patient improvement outcomes. In some embodiments, the Leicester Peripheral Field Test (LPFT) is used in the evaluation, and the Leicester Peripheral Field Test (LPFT) mean score and the Leicester Peripheral Field Test (LPFT) median score are determined. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 5-10 points after about 0.1-16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 5.2 points or about 6.3 points after about 0.1-16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 5.2 points or about 6.3 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 5-10 points after about 10-15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6 points to about 8 points after about 10-15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6.4 points or about 7.7 points after about 10-15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6.4 points or about 7.7 points after about 14 days.
[0094] In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5 to 10 points after about 0.1 to 16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5 to 10 points after about 5 to about 10 minutes. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5.2 points or about 6.3 points after about 0.1 to 16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5.2 points or about 6.3 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5.2 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6.3 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 7.7 points after about 2 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6.4 points after about 2 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5 to 10 points after about 10 to 15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6 points to about 8 points after about 10 to 15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6.4 points or about 7.7 points after about 10 to 15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 6.4 points or about 7.7 points after about 14 days.
[0095] In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 5-10 points after about 0.1-16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 7 points after about 0.1-16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) is used for evaluation, and a Leicester Peripheral Field Test (LPFT) average score and a Leicester Peripheral Field Test (LPFT) median score are determined. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-10 points after about 2 hours or about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 7 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 5-10 points after about 10-15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 9 points after about 10-15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score is increased by about 9 points after about 14 days.
[0096] In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-20 points after about 1-9 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-15 points after about 0.1-16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 10-15 points after about 0.1-16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-15 points after about 2-6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-15 points after about 1-14 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-10 points after about 1 day. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 5-10 points after about 14 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 5-10 points after about 14 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 5-10 points after about 0.1-16 hours.
[0097] In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 0.1 to 16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) mean score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 10 to 15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) average score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 14 days.
[0098] In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 0.1 to 16 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 6 hours. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 10 to 15 days. In some embodiments, the Leicester Peripheral Field Test (LPFT) median score increases by about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20 points after about 14 days.
[0099] In some embodiments, the Leicester Peripheral Field Test (LPFT) median score remains elevated for a period of about 10 minutes, about 20 minutes, about 1 hour, about 6 hours, about 8 hours, about 12 hours, or about 24 hours.
[0100] VIII. Marginal Corneal Reflex Distance 1 (MRD-1) Test The Marginal Reflex Distance 1 (MRD-1) test is performed using photometry to evaluate the distance from the central pupillary light reflex to the central edge of the upper eyelid. External digital photography is used to measure MRD-1. Measurements are based on the distance from the central pupillary light reflex to the central edge of the upper eyelid, ≤2mm (a visible central pupillary light reflex does not default to 0). The MRD-1 test is useful for evaluating the effectiveness of treatment.
[0101] In some embodiments, the marginal corneal reflex distance 1 test (MRD-1) is used to evaluate the patient's improvement outcome. In some embodiments, the marginal corneal reflex distance 1 test (MRD-1) is used to evaluate and determine the marginal corneal reflex distance 1 test (MRD-1) mean score and the marginal corneal reflex distance 1 test (MRD-1) median score. In some embodiments, the marginal corneal reflex distance 1 test (MRD-1) is performed, whereby the mean score increases by about 0.2 to 1.0 points after about 1 to 10 minutes. In some embodiments, the marginal corneal reflex distance 1 test (MRD-1) mean score increases by about 0.2 to 1.0 points after about 5 minutes. In some embodiments, the marginal corneal reflex distance 1 test (MRD-1) mean score increases by about 0.6 points after about 5 minutes. In some embodiments, the mean MRD-1 score increases by about 0.5 to 1.5 points after about 10 to 20 minutes. In some embodiments, the mean MRD-1 score increases by about 0.5 to 1.5 points after about 15 minutes. In some embodiments, the mean MRD-1 score increases by about 0.9 points after about 15 minutes.
[0102] In some embodiments, the mean lid marginal corneal reflex distance 1 test (MRD-1) score increases by about 0.5 to 1.5 points after about 5 minutes to about 16 hours. In some embodiments, the mean lid marginal corneal reflex distance 1 test (MRD-1) score increases by about 0.5 to 1.5 points after about 15 minutes to about 16 hours. In some embodiments, the mean lid marginal corneal reflex distance 1 test (MRD-1) score increases by about 0.5 to 1.5 points after about 15 minutes. In some embodiments, the mean score increases by about 0.2 to 1.0 points after about 5 minutes to about 16 hours. In some embodiments, the mean score increases by about 0.5 to 1.5 points after about 5 minutes to about 42 days.
[0103] In some embodiments, the mean MRD-1 score increases by about 1.5 points, about 1.4 points, about 1.3 points, about 1.2 points, about 1.1 points, about 1.0 points, about 0.9 points, about 0.8 points, about 0.7 points, about 0.6 points, about 0.5 points, about 0.4 points, or about 0.3 points after about 5 minutes to about 16 hours. In some embodiments, the mean MRD-1 score increases by about 1.5 points, about 1.4 points, about 1.3 points, about 1.2 points, about 1.1 points, about 1.0 points, about 0.9 points, about 0.8 points, about 0.7 points, about 0.6 points, about 0.5 points, about 0.4 points, or about 0.3 points after about 5 minutes. In some embodiments, the mean MRD-1 score increases by about 1.5 points, about 1.4 points, about 1.3 points, about 1.2 points, about 1.1 points, about 1.0 points, about 0.9 points, about 0.8 points, about 0.7 points, about 0.6 points, about 0.5 points, about 0.4 points, or about 0.3 points after about 15 minutes. In some embodiments, the mean MRD-1 score increases by about 1.5 points, about 1.4 points, about 1.3 points, about 1.2 points, about 1.1 points, about 1.0 points, about 0.9 points, about 0.8 points, about 0.7 points, about 0.6 points, about 0.5 points, about 0.4 points, or about 0.3 points after about 16 hours.
[0104] In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 1 to 20 minutes. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 5 minutes.
[0105] In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 10 to 20 minutes. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 15 minutes.
[0106] In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 2 to 12 hours. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 2 hours. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 6 hours.
[0107] In some embodiments, the mean lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 5 to 20 days. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 14 days.
[0108] In some embodiments, the mean lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 30 to 60 days. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) mean score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 42 days.
[0109] In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 1 to 20 minutes. In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1 to 16 hours, e.g., about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 0.1 to 16 hours, e.g., after 8 hours. In some embodiments, the marginal corneal reflex distance 1 (MRD-1) median score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 5 minutes.
[0110] In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 10 to 20 minutes. In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 15 minutes.
[0111] In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 2 to 12 hours. In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 2 hours. In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 6 hours.
[0112] In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 5 to 20 days. In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 14 days.
[0113] In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 30 to 60 days. In some embodiments, the median lid marginal corneal reflex distance 1 (MRD-1) score increases by about 0.1, about 0.2, about 0.3, about 0.4, about 0.5, about 0.6, about 0.7, about 0.8, about 0.9, about 1.0, about 1.1, about 1.2, about 1.3, about 1.4, about 1.5, about 1.6, about 1.7, about 1.8, about 1.9, or about 2.0 points after about 42 days.
[0114] IX. Pharmacokinetics In one embodiment, the dose comprises 2 drops of about 0.035 g / drop of a 0.1% by weight composition for a total dose of about 0.070 mg, with each drop of the pharmaceutical composition comprising about 0.035 mg of oxymetazoline hydrochloride. In another embodiment, each drop of the eye drop comprises 0.035 mg (0.1% oxymetazoline hydrochloride, which corresponds to 0.031 mg (0.088% of oxymetazoline free base equivalent)).
[0115] The compositions and methods of the present disclosure are useful for minimizing a patient's systemic exposure to oxymetazoline hydrochloride. In some embodiments, the mean AUC 0-∞ In some embodiments, the mean AUC of the pharmaceutical composition after administration of a single dose is about 300 to about 700 pg·h / mL. 0-∞ is approximately 468 pg·h / mL.
[0116] In some embodiments, the T of the pharmaceutical composition after administration of a single dose max In some embodiments, the T of the pharmaceutical composition after administration of a single dose is about 0.5 to about 6 hours. max In some embodiments, the T of the pharmaceutical composition after administration of a single dose is about 2 to 4 hours. max In some embodiments, the T of the pharmaceutical composition after administration of a single dose is about 0.5 to 4 hours. max is about 2 hours.
[0117] In some embodiments, the mean T of the pharmaceutical composition after administration of a single dose to a patient max is about 0.5 hours to about 12 hours, about 0.5 hours to about 10 hours, about 0.5 hours to about 8 hours, about 0.5 hours to about 6 hours, about 6 hours to about 12 hours, about 6 hours to about 10 hours, about 6 hours to about 8 hours, about 7 hours to about 12 hours, about 7 hours to about 10 hours, about 7 hours to about 8 hours, about 8 hours to about 12 hours, about 8 hours to about 10 hours, about 9 hours to about 12 hours, about 9 hours to about 10 hours, or about 10 hours to about 12 hours. max is about 0 hours to about 6 hours, about 1 hour to about 6 hours, about 1 hour to about 5 hours, about 2 hours to about 5 hours, about 2 hours to about 4 hours, or about 2 hours to about 3 hours. max In some embodiments, the median T max is about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, or about 10 hours.
[0118] In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose max In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 25 pg / ml to about 35 pg / ml. max In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 28-32 pg / ml. max is approximately 30.5 pg / ml.
[0119] In one embodiment, the dose comprises two drops of about 0.035 g / drop of a 0.1% by weight composition for a total dose of about 0.070 mg, the pharmaceutical composition comprising about 0.035 mg of oxymetazoline hydrochloride in each drop. In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose to a patient is max In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 10 pg / ml to about 40 pg / ml, about 12 pg / ml to about 38 pg / ml, about 14 pg / ml to about 36 pg / ml, about 16 pg / ml to about 34 pg / ml, about 18 pg / ml to about 32 pg / ml, or about 20 pg / ml to about 30 pg / ml.max is about 20 pg / ml, about 21 pg / ml, about 22 pg / ml, about 22 pg / ml, about 23 pg / ml, about 24 pg / ml, about 25 pg / ml, about 26 pg / ml, about 27 pg / ml, about 28 pg / ml, about 29 pg / ml, about 30 pg / ml, about 31 pg / ml, about 32 pg / ml, about 33 pg / ml, about 34 pg / ml, about 35 pg / ml, about 36 pg / ml, about 37 pg / ml, about 38 pg / ml, about 39 pg / ml, or about 40 pg / ml. In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 20 pg / ml, about 21 pg / ml, about 22 pg / ml, about 22 pg / ml, about 23 pg / ml, about 24 pg / ml, about 25 pg / ml, about 26 pg / ml, about 27 pg / ml, about 28 pg / ml, about 29 pg / ml, about 30 pg / ml, about 31 pg / ml, about 32 pg / ml, about 33 pg / ml, about 34 pg / ml, about 35 pg / ml, about 36 pg / ml, about 37 pg / ml, about 38 pg / ml, about 39 pg / ml, or about 40 pg / ml. max In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 25 pg / ml to about 35 pg / ml. max In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 28-32 pg / ml. max In some embodiments, the mean C of the pharmaceutical composition after administration of a single dose is about 30.5 pg / ml. max is approximately 30.5 pg / ml, and the geometric mean Cmax is approximately 28.3 pg / mL.
[0120] In some embodiments, the area under the mean plasma concentration-time curve (AUC 0-∞ In some embodiments, the mean AUC of the pharmaceutical composition after administration of a single dose is measured. 0-∞is about 0pg·h / mL to about 800pg·h / mL, about 50pg·h / mL to about 800pg·h / mL, about 50pg·h / mL to about 750pg·h / mL, about 100pg·h / mL to about 750pg·h / mL, about 100pg·h / mL to about 700pg·h / mL, about 150pg·h / mL to about 700pg·h / mL, about 150pg·h / mL to about 650pg·h / mL, about 200pg·h / mL to about 650pg·h / mL, about 200 pg·h / mL to about 600 pg·h / mL, about 250 pg·h / mL to about 600 pg·h / mL, about 250 pg·h / mL to about 550 pg·h / mL, about 300 pg·h / mL to about 550 pg·h / mL, about 300 pg·h / mL to about 500 pg·h / mL, about 350 pg·h / mL to about 500 pg·h / mL, about 400 pg·h / mL to about 500 pg·h / mL, or about 420 pg·h / mL to about 480 pg·h / mL. In some embodiments, the mean AUC 0-∞ is approximately 468 pg·h / mL.
[0121] In some embodiments, the geometric mean AUC of the pharmaceutical composition after administration of a single dose 0-∞ is about 0pg·h / mL to about 800pg·h / mL, about 50pg·h / mL to about 800pg·h / mL, about 50pg·h / mL to about 750pg·h / mL, about 100pg·h / mL to about 750pg·h / mL, about 100pg·h / mL to about 700pg·h / mL, about 150pg·h / mL to about 700pg·h / mL, about 150pg·h / mL to about 650pg·h / mL, about 200pg·h / mL to about 650pg·h / mL, about 200 pg·h / mL to about 600 pg·h / mL, about 250 pg·h / mL to about 600 pg·h / mL, about 250 pg·h / mL to about 550 pg·h / mL, about 300 pg·h / mL to about 550 pg·h / mL, about 300 pg·h / mL to about 500 pg·h / mL, about 350 pg·h / mL to about 500 pg·h / mL, about 400 pg·h / mL to about 500 pg·h / mL, or about 420 pg·h / mL to about 480 pg·h / mL. In some embodiments, the geometric mean AUC 0-∞ is approximately 439 pg·h / mL.
[0122] X. Packaging The storage format and packaging of the formulation are also important to maintain and deliver a consistent product. The packaging method of the present disclosure may involve the use of single unit dose containers formed from clear low density polyethylene (LDPE) resin. In some embodiments, the disposable containers are formed by a blow / fill / seal ("B / F / S" or "BFS") process. In some embodiments, the BFS process is carried out in a sterile environment. The BFS process is a process of forming, filling, and sealing containers in one continuous automated system, while the contents are kept sterile. BFS vials are continuously manufactured on a machine that extrudes plastic resin at high temperatures, rendering the resin sterile. Pellets are fed via gravity from a hopper at the top of the BFS machine into an extruder. The extruder heats the resin pellets to about 170°C to about 230°C, melting the plastic granules and producing a sterile extruded plastic tube (parison). The process begins by melting and extruding low density polyethylene (LDPE) resin to form a parison (hot resin in a hollow tubular form). The seal mold then closes to seal the vial, and the mold releases the filled and sealed vial. The entire process is performed without human intervention, reducing the risk of contamination. BFS vials can be filled upside down to ensure consistent filling, and sealed to form a "card" containing multiple vials. Sterile packaging techniques are important if the contents do not contain preservatives or antimicrobial agents. In some embodiments, the volume of the BFS vial is about 0.1 mL, about 0.2 mL, about 0.3 mL, about 0.4 mL, about 0.5 mL, about 0.6 mL, about 0.7 mL, about 0.8 mL, about 0.9 mL, or about 1.0 mL. In some embodiments, the volume of the BFS vial is about 1 mL, about 2 mL, about 3 mL, about 4 mL, about 5 mL, about 6 mL, about 7 mL, about 8 mL, about 9 mL, or about 10 mL. In some embodiments, the volume of the BFS vial is about 0.5 mL. In some embodiments, the BFS vial has a volume of 0.34 mL.
[0123] After BFS packaging, the containers can be enclosed in foil laminate pouches for individual packaging and / or child resistant zipper bags to prevent unwanted access. Pharmaceutical products typically require that product packaging comply with government regulations include child resistant features to prevent, for example, children under the age of five from accessing products that may cause serious illness or injury. Alternatively, the containers can be enclosed in child resistant foil laminate pouches. Child resistant pouch materials include PET, which can provide puncture resistance, machinability, integrity, and child resistance; May include aluminum foil, and / or a sealant.
[0124] The present disclosure is further illustrated by the following examples, which should not be construed as further limiting. The contents of all references cited throughout this application are expressly incorporated herein by reference. EXAMPLES
[0125] Example 1 formulation Oxymetazoline hydrochloride ophthalmic solution, 0.1% by weight, was manufactured in a batch size of 200 kg. The batch formulation of the drug product is shown in Table 1. [Table 1]
[0126] Formulation enhancements were pursued to improve the overall absorption of oxymetazoline in the eye without the use of preservatives. The vehicle formulation is a balanced salt solution intended for ocular irrigation, made to be at physiological pH and isotonic salt concentration. The addition of the excipient hypromellose, a viscosity modifier, helps provide additional residence time in the eye and improve ocular comfort. Eight development batches were tested using either hypromellose (HPMC) or sodium carboxymethylcellulose (NA CMC). The effect of this change on pH was also measured. Stability studies were performed at 25°C ± 2°C / 40% RH, 40°C ± 2°C / NMT25% RH, and 55°C / ambient RH. The compositions and results of these studies, including the 3-month stability study data, can be seen in Tables 2 and 3 below. [Table 2] [Table 3]
[0127] Example 2 PK analysis The following pharmacokinetic data was generated based on a dose of one drop in each eye, with each drop containing approximately 0.035 mg of oxymetazoline hydrochloride, for a total of 0.07 mg of oxymetazoline hydrochloride.
[0128] Parameter C max , AUC 0-∞ , and T max was evaluated based on a study population of 24 patients.
[0129] A study was conducted to determine the mean plasma oxymetazoline concentrations following administration of a single dose of oxymetazoline hydrochloride ophthalmic solution, 0.1% by weight. The results of the study are detailed in Figure 1, Table 4, and Table 5. [Table 4] [Table 5]
[0130] Example 3 Phase 3 Data, Study 1 Study 1: This study was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of the safety and efficacy of once-daily (QD) treatment (1 drop per eye) with oxymetazoline hydrochloride ophthalmic solution, 0.1%, compared to vehicle in subjects with acquired ptosis. A total of 140 subjects were randomized in an approximate 2:1 ratio, i.e., oxymetazoline hydrochloride 0.1% by weight QD (N=94); vehicle (N=46) at 16 sites. Oxymetazoline hydrochloride was administered topically for 42 days (6 weeks). The study was conducted in two periods, i.e., period 1 (safety and efficacy) duration was 2 weeks and period 2 (long-term safety and comfort) duration was 4 weeks. The mean age of subjects was 64.2 years.
[0131] 3.2 Effectiveness Efficacy was assessed by photometric measurements of the LPFT (primary) and MRD-1. The primary efficacy outcome was hierarchically ordered to compare oxymetazoline hydrochloride with vehicle in terms of the mean increase from baseline (Day 1, Time 0) in the number of points in the top 4 lines of the LPFT in the study eye as follows: 1. Day 1 Time 6 2. Time 2 on the 14th day The study has been completed and the results are shown below. The increase in the number of points seen in the upper visual field (change in LPFT) for the oxymetazoline hydrochloride group compared to the vehicle group at both time points was statistically significant. This shows that the improvement in the upper visual field is evident at 6 hours post-dose on Day 1 and 2 hours post-dose on Day 14 in Table 6. The mean change from baseline in visual field data at Day 14, Time 6, Day 14, Time 8, and Day 42 can be seen in Table 7. [Table 6] [Table 7]
[0132] Example 4 Phase 3 Data, Study 2 Study 2: This study was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study of the safety and efficacy of once-daily (QD) treatment with oxymetazoline hydrochloride (1 drop per eye) compared to vehicle in subjects with acquired ptosis. A total of 164 subjects were randomized in an approximate 2:1 ratio, i.e., oxymetazoline hydrochloride 0.1% by weight QD (N=109); vehicle (N=55) at 27 sites. Oxymetazoline hydrochloride 0.1% by weight was administered topically for 42 days (6 weeks). The study was conducted in two periods, i.e., period 1 (safety and efficacy) duration was 2 weeks and period 2 (long-term safety and comfort) duration was 4 weeks. The mean age of subjects was 63.5 years. One subject was under 18 years of age.
[0133] 4.1 Effectiveness Efficacy was assessed by photometric measurements of the LPFT (primary) and MRD-1. The primary efficacy outcome was hierarchically ordered to compare oxymetazoline hydrochloride with vehicle in terms of the mean increase from baseline (Day 1, Time 0) in the number of points in the top 4 lines of the LPFT in the study eye as follows: 1. Day 1 Time 6 2. Time 2 on the 14th day The results are shown below. The increase in the number of points in the upper visual field (change in LPFT) for the oxymetazoline hydrochloride group compared to the vehicle group at both time points was statistically significant. This shows that the improvement in the upper visual field is evident at 6 hours post-dose on Day 1 and 2 hours post-dose on Day 14 in Table 8.
[0134] Photographic measurements of MRD-1 also demonstrated a positive effect of oxymetazoline hydrochloride treatment. Increases in LPFT were numerically greater in the oxymetazoline hydrochloride group than in the vehicle group at all time points after dosing. Greater increases in MRD-1 were observed for the oxymetazoline hydrochloride group than in the vehicle group at all time points after 6 weeks of dosing, Table 9. Increases in MRD-1 values observed 5 minutes after dosing indicated an onset of action by 5 minutes.
[0135] 4.2 Safety Oxymetazoline hydrochloride was well tolerated and observed AEs were primarily mild in intensity.
[0136] 4.3 Results The LPFT was performed using the Humphrey Visual Field Analyzer. It is an age-corrected screening test that uses a three-zone strategy. 35 points are tested in the upper visual field and 14 points are tested in the lower visual field. A maximum of 48° is tested in the upper visual field. The center of fixation is shifted downward by 15° to allow for maximum upper visual field testing (Ho et al., 2011). The lower visual field test serves as a baseline but is not used in the analysis. A representative Leicester Peripheral Visual Field Test grid can be seen in Figure 2. The subject holds the forehead against the chin and chin, keeping the forehead still and the forehead relaxed. The subject views the fixation target throughout the test. Corrective lenses are not required for the LPFT unless the subject has difficulty seeing the target without them (e.g., high myopia, high hyperopia, or high astigmatism). [Table 8] [Table 9]
[0137] Example 5 Stability of oxymetazoline hydrochloride formulations Stability studies were conducted on oxymetazoline hydrochloride formulations over a 24 month period at 40% relative humidity. The results of the stability studies are shown in Table 10 below, and vehicle stability data can be found in Table 11. [Table 10] [Table 11]
[0138] Oxymetazoline hydrochloride solution was stable over five measurement time points: 0, 6, 12, 18, and 24 months, indicating good stability and shelf life of the formulated preparation.
[0139] Example 6 Clinical supply stability study of oxymetazoline hydrochloride Oxymetazoline hydrochloride formulations were prepared according to Table 12. Stability studies were performed on the oxymetazoline preparations over periods ranging from 24 to 30 months. [Table 12]
[0140] Three commercial-scale, one-step process batches (R60681, R60701, and R60711) were tested at the end of their shelf life. The results support the proposed 24-month shelf life. The 24-month and 30-month stability data are shown in Figures 3A-B, 4A-B, and 5A-B for each batch (R60681, R60701, and R60711, respectively).
[0141] Throughout this application, various publications are referenced in parentheses by author name and date, or patent or patent publication number. The disclosures of these publications are hereby incorporated by reference in their entireties into this application in order to more fully describe the state of the art as of the date of the present disclosure as described and claimed herein, as known to those skilled in the art. However, the citation of a reference herein should not be construed as an admission that such reference is prior art to the present disclosure. In an embodiment of the present invention, for example, the following items are provided: (Item 1) a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.2% to about 1.0% by weight of sodium chloride; c) about 0.05% to about 0.10% by weight of potassium chloride; d) about 0.02% to about 0.06% by weight of calcium chloride; e) about 0.01% to about 0.05% by weight of magnesium chloride; f) one or more suitable buffers; g) about 0.1% by weight to about 0.90% by weight of hypromellose; h) a pH adjuster, if necessary; 1. A pharma- ceutical stable, aqueous ophthalmic formulation comprising: The formulation has a pH in the range of about 6.3 to about 6.5. (Item 2) 2. The formulation of item 1, wherein the one or more suitable buffers comprise from about 0.05% to about 1.0% by weight. (Item 3) 3. The formulation of item 2, wherein the one or more suitable buffers comprise sodium acetate trihydrate and sodium citrate. (Item 4) 4. The formulation of item 3, wherein the one or more suitable buffers comprise about 0.39% by weight of sodium acetate trihydrate and about 0.17% by weight of sodium citrate. (Item 5) 2. The formulation of item 1, wherein the formulation comprises about 0.64% by weight of sodium chloride, about 0.075% by weight of potassium chloride, about 0.048% by weight of calcium chloride dihydrate, and about 0.03% by weight of magnesium chloride hexahydrate. (Item 6) 2. The formulation of claim 1, wherein the pH adjusting agent is selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and combinations thereof. (Item 7) 7. The formulation of item 6, wherein the pH adjusting agent comprises hydrochloric acid. (Item 8) 2. The formulation according to item 1, wherein the formulation is preservative-free. (Item 9) 9. The formulation of item 8, wherein the formulation is stable for 0 to 24 months. (Item 10) 9. The formulation of item 8, wherein the formulation is stable for at least 24 months. (Item 11) 11. The formulation according to item 10, wherein the formulation is stable at 25° C. and 40% relative humidity for at least 24 months. (Item 12) 9. A disposable container containing the formulation according to item 8. (Item 13) Item 13. The disposable container according to item 12, wherein the volume of the disposable container is about 0.5 mL. (Item 14) Item 14. The disposable container according to item 13, wherein the disposable container is in a child resistant pouch. (Item 15) Item 13. The disposable container according to item 12, wherein the disposable container delivers about 0.035 mg of oxymetazoline hydrochloride per drop. (Item 16) a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.2% to about 1.0% by weight of sodium chloride; c) about 0.05% to about 0.10% by weight of potassium chloride; d) about 0.02% to about 0.06% by weight of calcium chloride; e) about 0.01% to about 0.05% by weight of magnesium chloride; f) one or more suitable buffers; g) about 0.1% by weight to about 0.90% by weight of hypromellose; h) a pH adjuster, if necessary; A pharma- ceutical stable, aqueous ophthalmic formulation comprising: The formulation has a pH in the range of about 6.3 to about 6.5. (Item 17) 17. The formulation of item 16, wherein the one or more suitable buffers comprise from about 0.05% to about 1.0% by weight. (Item 18) 18. The formulation of item 17, wherein the one or more suitable buffers comprise sodium acetate trihydrate and sodium citrate. (Item 19) 19. The formulation of item 18, wherein the one or more suitable buffers comprise about 0.39% by weight of sodium acetate trihydrate and about 0.17% by weight of sodium citrate. (Item 20) 17. The formulation of item 16, wherein the formulation comprises about 0.64% by weight of sodium chloride, about 0.075% by weight of potassium chloride, about 0.048% by weight of calcium chloride dihydrate, and about 0.03% by weight of magnesium chloride hexahydrate. (Item 21) 17. The formulation of item 16, wherein the pH adjuster is selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and combinations thereof. (Item 22) 22. The formulation of item 21, wherein the pH adjusting agent comprises hydrochloric acid. (Item 23) 17. The formulation according to item 16, wherein the formulation is stable for 0 to 24 months. (Item 24) 17. The formulation of item 16, wherein the formulation is stable for at least 24 months. (Item 25) 25. The formulation according to item 24, wherein the formulation is stable at 25° C. and 40% relative humidity for at least 24 months. (Item 26) 17. A disposable container comprising the formulation according to item 16. (Item 27) 27. The disposable container according to item 26, wherein the volume of the disposable container is about 0.5 mL. (Item 28) 27. The disposable container according to item 26, wherein the disposable container is in a child-resistant package. (Item 29) 27. The disposable container of item 26, wherein the disposable container delivers about 0.035 mg of oxymetazoline hydrochloride per drop. (Item 30) 1. A pharma- ceutical lysable, aqueous, preservative-free ophthalmic formulation comprising: a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.64% by weight of sodium chloride; c) about 0.075% by weight of potassium chloride; d) about 0.048% by weight of calcium chloride dihydrate; e) about 0.03% by weight of magnesium chloride hexahydrate; f) one or more suitable buffers; g) about 0.5% by weight of hypromellose; h) optionally hydrochloric acid; i) A formulation, wherein the pH of the formulation is in the range of about 6.3 to about 6.5. (Item 31) 1. A method of treating ptosis in a subject, the method comprising administering to at least one eye of the subject: a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.2% to about 1.0% by weight of sodium chloride; c) about 0.05% to about 0.10% by weight of potassium chloride; d) about 0.02% to about 0.06% by weight of calcium chloride; e) about 0.01% to about 0.05% by weight of magnesium chloride; f) one or more suitable buffers; g) about 0.1% by weight to about 0.90% by weight of hypromellose; h) with hydrochloric acid as required; administering a therapeutically effective amount of a pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprising The method, wherein the pharma- ceutically stable aqueous ophthalmic formulation has a pH range of about 6.3 to about 6.5. (Item 32) 32. The method of claim 31, wherein the ptosis is acquired aponeurotic ptosis. (Item 33) 32. The method of claim 31, wherein the pharma- ceutical stable aqueous ophthalmic formulation is administered to the subject at a dose of one drop in each eye for one or more consecutive days for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride. (Item 34) The mean C after administration of a single dose of the formulation max is about 25 to about 35 pg / ml. (Item 35) Mean AUC after administration of a single dose of the formulation 0-∞ Item 34. The method according to Item 33, wherein the serum albumin is about 300 to about 700 pg h / mL. (Item 36) T after administration of a single dose of the formulation max Item 34. The method according to Item 33, wherein the heating time is about 0.5 to about 6 hours. (Item 37) The pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprises: a) about 0.64% by weight of sodium chloride; b) about 0.075% by weight of potassium chloride; c) about 0.048% by weight of calcium chloride dihydrate; d) about 0.03% by weight of magnesium chloride hexahydrate; e) about 0.5% by weight of hypromellose; 32. The method according to claim 31, comprising: (Item 38) 1. A method of increasing vertical separation between an upper eyelid and a lower eyelid of at least one eye of a subject, the method comprising administering to at least one eye of the subject: f) about 0.1% by weight of oxymetazoline hydrochloride; g) about 0.2% to about 1.0% by weight of sodium chloride; h) about 0.05% by weight to about 0.10% by weight of potassium chloride; i) about 0.02% to about 0.06% by weight of calcium chloride; j) about 0.01% to about 0.05% by weight of magnesium chloride; k) one or more suitable buffers; l) about 0.1% by weight to about 0.90% by weight of hypromellose; m) with hydrochloric acid as required; and administering a pharma- ceutical stabilised, aqueous, preservative-free ophthalmic formulation comprising: The method, wherein the pharma- ceutically stable aqueous ophthalmic formulation has a pH range of about 6.3 to about 6.5. (Item 39) 39. The method of claim 38, wherein the formulation is administered to the subject in a dose of one drop in a single eye for one or more consecutive days for a total daily dose of about 0.035 mg of oxymetazoline hydrochloride. (Item 40) 39. The method of claim 38, wherein the formulation is administered to the subject at a dose of one drop in each eye for one or more consecutive days for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride. (Item 41) The mean C after administration of a single dose of the formulation max is about 25 to about 35 pg / ml. (Item 42) Mean AUC after administration of a single dose of the formulation 0-∞ is about 300 to about 700 pg h / mL. (Item 43) T after administration of a single dose of the formulation maxItem 41. The method according to Item 40, wherein the heating time is about 0.5 to about 6 hours. (Item 44) The pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprises: a) about 0.64% by weight of sodium chloride; b) about 0.075% by weight of potassium chloride; c) about 0.048% by weight of calcium chloride dihydrate; d) about 0.03% by weight of magnesium chloride hexahydrate; e) about 0.5% by weight of hypromellose; 39. The method according to claim 38, comprising: (Item 45) 1. A method of improving a Leicester Peripheral Field Test (LPFT) score in a subject, the method comprising administering to at least one eye of the subject: a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.2% to about 1.0% by weight of sodium chloride; c) about 0.05% to about 0.10% by weight of potassium chloride; d) about 0.02% to about 0.06% by weight of calcium chloride; e) about 0.01% to about 0.05% by weight of magnesium chloride; f) one or more suitable buffers; g) about 0.1% by weight to about 0.90% by weight of hypromellose; h) with hydrochloric acid as required; and administering a pharma- ceutical stabilised, aqueous, preservative-free ophthalmic formulation comprising: The method, wherein the pharma- ceutical stable aqueous ophthalmic formulation has a pH range of about 6.3 to about 6.5, and the mean LPFT score increases by about 5 to 10 points about 0.1 to 16 hours after administration. (Item 46) 46. The method of claim 45, wherein the formulation is administered to the subject at a dose of one drop in each eye for one or more consecutive days for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride. (Item 47) The mean C after administration of a single dose of the formulation maxis about 25 to about 35 pg / ml. (Item 48) Mean AUC after administration of a single dose of the formulation 0-∞ Item 47. The method according to item 46, wherein the serum albumin is about 300 to about 700 pg h / mL. (Item 49) T after administration of a single dose of the formulation max Item 47. The method according to Item 46, wherein the heating time is about 0.5 to about 6 hours. (Item 50) 46. The method according to item 45, wherein the median score on the Leicester Peripheral Field Test (LPFT) is increased by about 5 to 10 points about 6 hours after administration. (Item 51) 46. The method according to item 45, wherein no tachyphylaxis is exhibited for at least 6 weeks. (Item 52) The pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprises: a) about 0.64% by weight of sodium chloride; b) about 0.075% by weight of potassium chloride; c) about 0.048% by weight of calcium chloride dihydrate; d) about 0.03% by weight of magnesium chloride hexahydrate; e) about 0.5% by weight of hypromellose; Item 46. The method according to item 45, comprising: (Item 53) 1. A method of improving a Marginal Reflex Distance Test 1 (MRD-1) score in a subject, the method comprising administering to at least one eye of the subject: a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.2% to about 1.0% by weight of sodium chloride; c) about 0.05% to about 0.10% by weight of potassium chloride; d) about 0.02% to about 0.06% by weight of calcium chloride; e) about 0.01% to about 0.05% by weight of magnesium chloride; f) one or more suitable buffers; g) about 0.1% by weight to about 0.90% by weight of hypromellose; h) with hydrochloric acid as required; and administering a pharma- ceutical stabilised, aqueous, preservative-free ophthalmic formulation comprising: wherein the pharmacologic agent is a medicament for treating a patient with a cataract, the pharmacologic agent being medicament for treating a patient with a cataract, and the pharmacologic agent is a medicament for treating a patient with a cataract, the pharmacologic agent being ... (Item 54) 54. The method of claim 53, wherein the pharma- ceutical stable aqueous ophthalmic formulation is administered to the subject at a dose of one drop in each eye for one or more consecutive days for a total daily dose of about 0.07 mg of oxymetazoline hydrochloride. (Item 55) The mean C after administration of a single dose of the formulation max is about 25 to about 35 pg / ml. (Item 56) Mean AUC after administration of a single dose of the formulation 0-∞ Item 55. The method according to Item 54, wherein the serum albumin is about 300 to about 700 pg h / mL. (Item 57) T after administration of a single dose of the formulation max Item 55. The method according to item 54, wherein the heating time is about 0.5 to about 6 hours. (Item 58) 54. The method according to item 53, wherein the mean score of the marginal corneal reflex distance test 1 (MRD-1) is increased by about 0.2 to 1.0 points about 5 minutes after administration. (Item 59) 54. The method of item 53, wherein no tachyphylaxis is exhibited for at least 6 weeks. (Item 60) The pharma- ceutical stable, aqueous, preservative-free ophthalmic formulation comprises: a) about 0.64% by weight of sodium chloride; b) about 0.075% by weight of potassium chloride; c) about 0.048% by weight of calcium chloride dihydrate; d) about 0.03% by weight of magnesium chloride hexahydrate; e) about 0.5% by weight of hypromellose; 54. The method according to item 53, comprising:
Claims
1. a) about 0.1% by weight of oxymetazoline hydrochloride; b) about 0.2% to about 1.0% by weight of sodium chloride; c) about 0.05% to about 0.10% by weight of potassium chloride; d) about 0.02% to about 0.06% by weight of calcium chloride or its hydrate; e) about 0.01% to about 0.05% by weight of magnesium chloride or a hydrate thereof; f) one or more suitable buffers; g) about 0.25% to about 1% by weight of sodium carboxymethylcellulose; h) optionally a pH adjuster; i) Water for injection; wherein the pH of said formulation ranges from about 5.6 to about 6.
6.
2. The formulation of claim 1, wherein the formulation comprises about 0.25% by weight, about 0.5% by weight, or about 1% by weight sodium carboxymethylcellulose.
3. The formulation, b) about 0.64% by weight of sodium chloride; c) about 0.075% by weight of potassium chloride; d) about 0.048% by weight of calcium chloride or its hydrate; e) about 0.03% by weight of magnesium chloride or its hydrate; The formulation of claim 1 , comprising:
4. The formulation of claim 1, wherein the calcium chloride or its hydrate is calcium chloride dihydrate and the magnesium chloride or its hydrate is magnesium chloride hexahydrate.
5. The formulation of claim 1, wherein the buffer comprises sodium acetate or a hydrate thereof and sodium citrate or a hydrate thereof.
6. The formulation of claim 1, wherein the buffer comprises about 0.39% by weight sodium acetate or a hydrate thereof and about 0.17% by weight sodium citrate or a hydrate thereof.
7. The formulation of claim 1, wherein the buffer comprises sodium acetate trihydrate and sodium citrate dihydrate.
8. The formulation of claim 1, wherein the pH of the formulation is about 5.6, about 5.8, about 6.0, about 6.5, or about 6.
6.
9. The formulation of claim 1, wherein the pH adjuster is selected from the group consisting of acetic acid, hydrochloric acid, sulfuric acid, fumaric acid, phosphoric acid, calcium acetate, calcium carbonate, ammonium bicarbonate, ammonium sulfate, sodium hydroxide, ammonium hydroxide, ammonium phosphate, and combinations thereof.
10. The formulation of claim 5, wherein the pH adjuster comprises hydrochloric acid.
11. The formulation of claim 1, wherein the formulation does not contain a preservative.
12. The formulation of claim 1, wherein the viscosity of the formulation is from about 15 cPs to about 35 cPs.
13. The formulation of claim 1, wherein the viscosity of the formulation is from about 15 cPs to about 25 cPs.
14. The formulation of claim 1, wherein the osmolality of the formulation is from about 290 to about 365 mOsm / kg.
15. The formulation of claim 1, wherein the osmolality of the formulation is from about 290 to about 330 mOsm / kg.
16. The formulation of claim 1, wherein the formulation is filled in a disposable container.
Citation Information
Patent Citations
Compositions and methods for non-surgical treatment of ptosis
JP2014506927A
